Basilea Pharmaceutica, a commercial-stage biopharmaceutical company, agreed to acquire fosmanogepix, a clinicalstage broad-spectrum antifungal candidate of Amplyx Pharmaceuticals, an affiliate of Pfizer, for $543m. Financial terms were not disclosed. “With fosmanogepix, we are adding a very promising drug candidate to our late-stage clinical antifungal pipeline. It has the potential to become an important treatment option for difficult-to-treat, invasive fungal infections. We plan to initiate the first phase 3 study with fosmanogepix mid-2024. This is a transformative transaction for us, as it provides a strong commercial near-term opportunity beyond our currently marketed anti-infectives Cresemba and Zevtera. We have now executed three transactions over the course of the last few weeks that have significantly strengthened our clinical-stage portfolio, and we continue to see interesting opportunities for further transactions in the future,” David Veitch, Basilea Chief Executive Officer.